Hematology Xagena

Xagena Mappa
Medical Meeting

Search results for "CTL019"

Eight of 14 patients in the first trial of the University of Pennsylvania’s personalized cellular therapy for chronic lymphocytic leukemia ( CLL ) responded to the therapy, with some complete remissio ...

Ninety-three percent of pediatric patients ( 55 of 59 ) with relapsed/refractory acute lymphoblastic leukemia ( ALL ) went into remission after receiving an investigational therapy made from their own ...

The European Commission ( EC ) has approved Kymriah ( Tisagenlecleucel, formerly CTL019 ). The approved indications are for the treatment of pediatric and young adult patients up to 25 years of age wi ...